“Our investors have articulated that what will transform the potential of Halozyme is success in pancreas cancer,” CEO Helen Torley told the San Diego Business Journal in March.

“Our investors have articulated that what will transform the potential of Halozyme is success in pancreas cancer,” CEO Helen Torley told the San Diego Business Journal in March. Photo by Jamie Scott Lytle.

San Diego’s Halozyme is headed for an inflection point...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129